Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lucanix Phase II in NSCLC
NCT01058785Phase 2Completed
- Sponsor
- NovaRx Corporation
- Start
- Mar 2003
- Primary completion
- Dec 2005
- Modality
- Prophylactic Vaccines, Whole Cell Cancer Vaccines, Modified DNA Oligonucleotides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of belagenpumatucel-l in non-small cell lung cancer (NSCLC) (3 arms), sponsored by NovaRx Corporation. Primary endpoint: Tumor Response. Started Mar 2003; status: completed.
02
Drugs
belagenpumatucel-l
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01058785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01058785.